Home>Topics>Stocks>Idenix Pharmaceuticals

Idenix Pharmaceuticals IDIX

  1. All
  2. Commentary
  3. Headlines
    1. Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential

      Headlines

      Tue, 12 Aug 2014

      By R.S. Analytics : Arrowhead Research Corp. (NASDAQ: ARWR ) is a biopharmaceutical company targeting RNAi therapeutics. There are multiple compounds in Arrowhead's pipeline but the highest priority compound, and the focus of this article, is ARC-520 for hepatitis B. ARC-520 is being studied as a

    2. Enanta Pharmaceuticals Is Simply Too Cheap To Ignore

      Headlines

      Mon, 11 Aug 2014

      figures, Merck & Co. (NYSE: MRK ) decided to bolster its own hepatitis C franchise with the purchase of Idenix Pharmaceuticals (NASDAQ: IDIX ) earlier this year for $3.85 billion. While that figure pales in comparison to Gilead's purchase

    3. Merck: Should You Buy It?

      Headlines

      Mon, 11 Aug 2014

      By Balanced Investing : The players of the drug manufacturing industry constantly grapple with the reality of patent expiries. Merck (NYSE: MRK ), being one of the renowned companies in the industry, is continuously on the move to commercialize its new wave of innovative discoveries to maintain and

    4. Gilead Is Going To Make More Money In The Future

      Headlines

      Wed, 6 Aug 2014

      coincided with a timely piece at the time of concern surrounding patent litigation and Merck & Co.'s (NYSE: MRK ) buyout of Idenix (NASDAQ: IDIX ). Beyond intellectual property, Idenix has experimental hepatitis C products Complete Story »

    5. Gilead: A Growth Story

      Headlines

      Wed, 6 Aug 2014

      By Don Dion : Due to the recent release of its blockbuster hepatitis-C drug, Sovaldi, that is estimated to have nearly $5 billion in sales in the first 6-months of 2014, Gilead Sciences Inc. (NASDAQ: GILD ) is fighting a legal battle to hold off competitors who are claiming patent infringement and

    6. Idenix Pharmaceuticals misses by $0.22

      Headlines

      Thu, 31 Jul 2014

      Idenix Pharmaceuticals (NASDAQ: IDIX ): Q2 EPS of -$0.43 misses by $0.22 . Press Release Post your comment!

    7. Wall Street Breakfast: Tax Inversions, Solar Tariffs, Samsung Delay

      Headlines

      Mon, 28 Jul 2014

      author receives $2,500. Read more about Outstanding Performance awards here . Winner #1: Long idea on IDIX ( Idenix Pharmaceuticals ) by Unconventional Capital Wisdom, published July 30, 2013. Return to date: +597% Winner #2: Long

    8. A Pre-Earnings Update On Gilead

      Headlines

      Thu, 10 Jul 2014

      By DoctoRx : Background : Gilead Sciences ( GILD ) may remain substantially undervalued relative to the market despite its tremendous stock price appreciation recently and over many years. The following shows GILD versus the S&P 500 and the NASDAQ since this Yahoo! Finance chart begins with ...

    9. Merck to buy Idenix for about $3.85 billion

      Headlines

      Mon, 9 Jun 2014

      June 9 (Reuters) - Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.

    10. Idenix shares rise on promising mid-stage hep C data

      Headlines

      Wed, 20 Jun 2012

      (Reuters) - Shares of Idenix Pharmaceuticals Inc rose as much as 16 percent on Wednesday, after the company reported positive mid-stage trial data of its hepatitis C drug, suggesting it was closer...

    « Prev123Next »
    Content Partners